Posted by Michael Wonder on 23 Dec 2018
Notification of a new drug application for HP-3070 (transdermal patch for the treatment of schizophrenia) in the U.S
17 December 2018 - Hisamitsu Pharmaceutical announces that a New Drug Application has been submitted to the U.S. FDA seeking approval of HP-3070 (asenapine) transdermal system for the treatment of schizophrenia.
The investigational product is a systemic transdermal formulation developed using Hisamitsu Pharmaceutical’s transdermal drug delivery system technology. Hisamitsu Pharmaceutical expects the investigational product to be a new option in the treatment of schizophrenia.
